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Le glaucome à angle ouvert est une neuropathie optique chronique progressive pour 
laquelle de nombreux traitements tant médicaux que chirurgicaux ont été proposés. 
La prise en charge chirurgicale s'articule principalement autour de deux chirurgies 
filtrantes, la trabéculectomie et la sclérectomie profonde avec implant de collagène. 
Cependant, les complications postopératoires de ces deux interventions étant 
relativement fréquentes, la recherche s'est orientée vers des traitements alternatifs 
dont la mise en place de micro-drains. Ces implants de drainage diminuent la 
pression intraoculaire en créant un court-circuit du flux d'humeur aqueuse de la 
chambre antérieure vers l'espace sous-conjonctival avec formation d'une bulle de 
filtration. L'implant Ex-PRESS R-50 est un implant miniature (2.5 mm de long pour 
400 µm de diamètre) en acier inoxydable et biocompatible. 
La présente étude s'est proposée d'étudier l'efficacité et la sécurité de l'implant 
miniature Ex-Press R-50 lors d'une opération combinée cataracte-glaucome. Trente-
cinq yeux de 35 patients (âge moyen: 75 ans) ont été inclus dans l'étude. Tous les 
patients ont bénéficié d'une opération de la cataracte par phacoemulsification et mise 
en place d'un implant de chambre postérieure suivie de l'implantation du micro-drain. 
Les pressions intraoculaires préopératoires et postopératoires, la meilleure acuité 
visuelle corrigée, le nombre de médicaments anti-glaucomateux ainsi que le type et 
le nombre de complications ont été évalués mensuellement puis tous les 6 mois 
pendant 4 ans. Le succès total a été défini par une pression postopératoire finale 
inférieure à 18mmHg sans traitement médical associé, le succès partiel par une 
pression postopératoire finale inférieure à 18mmHg avec ou sans traitement médical 
associé. 
Le suivi moyen a été de 36.9 mois avec une baisse de la pression intraoculaire 
significative d'environ 25%. Une augmentation de l'acuité visuelle a été observée 
après l'opération de la cataracte et le nombre de médicaments anti-glaucomateux a 
été réduit de 57%. Dix patients ont bénéficié d'un traitement supplémentaire de la 
bulle de filtration par injection d'anti-métabolite (mitomycine C). Nous avons observé 
8 complications majeures (4 érosions conjonctivales et 4 obstructions de l'orifice 
interne du micro-drain), toutes suivies de l'ablation de l'implant et de la réalisation 
d'une chirurgie classique du glaucome. En se basant sur les courbes de Kaplan-
Meier à 48 mois, le taux de succès total était de 32.7% et le succès partiel de 53.7%. 
Nous pouvons conclure suite à ce travail que l'implant miniature Ex-PRESS R-50 est 
associé à un nombre trop élevé de complications, même si les cas non compliqués 
ont bénéficié d'une baisse significative de la pression intraoculaire. La modification 
de l'architecture du micro-drain ainsi que de la technique chirurgicale devrait 
augmenter le taux de succès. 
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PURPOSE: To evaluate the efficacy and safety of the Ex-PRESS R-50 implant (Optonol Ltd.) in eyes 
operated on for open-angle glaucoma combined with phacoemulsification. 
SETTING: Glaucoma Unit, Ophthalmology Department, University of Lausanne, Lausanne, 
Switzerland. 
METHODS: Between November 2000 and June 2002, the Ex-PRESS R-50 shunt was implanted in 35 
eyes of 35 patients. The best corrected visual acuity (BCVA), intraocular pressure (IOP), number of 
medications, and complications were recorded preoperatively as well as postoperatively at 1 and 7 
days and 1, 2, 3, 6, 9, 12, 24, 36, and 48 months. Temporal clear corneal phacoemulsification with 
intraocular lens implantation was performed first. The ophthalmic viscosurgical device was not re-
moved, and the Ex-PRESS R-50 was implanted under the conjunctiva into the anterior chamber. 
RESUL TS: The mean follow-up was 36.9 months ± 18.2 (SD) and the mean age of the patients, 
7 4.6 ± 10.9 years. The mean preoperative IOP of 19.3 ± 6.3 mm Hg decreased postoperatively 
to 15.3 ± 6.2 mm Hg, 15.1 ± 4.6 mm Hg, 13.8 ± 2.8 mm Hg, 14.6 ± 2.9 mm Hg, and 13.3 ± 
2.0 mm Hg at 6 months, 12 months, 24 months, 36 months, and 48 months, respectively (P<.005). 
At 48 months, the mean BCVA was 0.74 ± 0.34 and the number of medications was reduced by 
57% (P<.005). The microtube was removed in 10 patients, and bleb management was performed 
in 10 eyes. Ten patients (32%) had satisfactory IOP control (mean 13.2 ± 2.2 mm Hg) without 
medication; minor transie nt complications were observed in 1 O patients. Based on the cumulative 
survival curve after 48 months, the complete success rate was 32.7% and the qualified success 
rate, 53.7% (P<.05). 
CONCLUSIONS: Ex-PRESS R-50 implantation under the conjunctiva was associated with a relatively 
high number of complications, des pite good IOP control in the uncomplicated cases. Refinement in 
the tube design and implantation technique would increase the success rate. 
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Deep sclerectomy with collagen implant surgery was 
initially designed to lower the complication rates en-
countered with the most commonly used penetrating 
procedure, trabeculectomy.1 Complications included 
hyphema, anterior chamber inflammation, excessive 
filtration leading to hypotony, a flat anterior chamber, 
surgery-induced cataract, choroidal detachment, 
hypotony-related maculopathy, and endophthalmitis. 
Because deep sclerectomy is a nonpenetrating proce-
dure, most complications were avoided or signifi-
cantly reduced. Despite these advantages, the 
technique has drawbacks, such as a relatively long 
learning curve and a delicate surgical technique, that 
explain the relatively high rate of conversion from 
deep sclerectomy to trabeculectomy during surgery. 2 
1946 © 2007 ASCRS and ESCRS 
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To alleviate the complications, the search for alterna-
tive treatments to conventional glaucoma filtering sur-
gery has intensified and penetrating filtering surgery 
using miniature glaucoma drainage devices has 
gained renewed interest since the introduction of large 
drainage devices almost a century ago. 3,4 These de-
vices create alternative aqueous pathways by draining 
aqueous from the anterior chamber through a long 
tube to an equatorial plate that promotes bleb forma-
tion.5 They have been commonly used in refractory 
glaucoma when other modes of treatment, nonsurgical 
and surgical, have failed. 6'7 Results in such cases of 
complicated glaucoma were difficult to analyze, and 
no definitive conclusions could be drawn from these 
studies. However, experience in the use of such 
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devices led to several modifications in their design and 
construction and in the techniques for their 
1 . 8 imp antatlon. 
The first miniature glaucoma implant, the Ex-PRESS 
R-50 (Optonol Ltd.), was developed in 1998. The im-
plant is a nonvalved device that is implanted at the 
!imbus to drain aqueous humor from the anterior 
chamber to the subconjunctival space, creating a con-
junctival filtration bleb, similar to trabeculectomy.9 
Severa! articles on the Ex-PRESS R-50 implant have 
been published. Five studies of 26, 24, 16, 50, and 99 
eyes, respectively, found encoura~ing results with 
a safe and efficient procedure.10- 1 Two case series 
with 11 and 4 eyes, respectively, and 1 case report con-
cluded that the complication rate was unacceptably 
high, in particular with respect to the risk for endoph-
thalmitis after conjunctival erosion. 15- 17 
The purpose of this study was to evaluate the 
efficacy and safety of the Ex-PRESS R-50 miniature 
glaucoma implant placed under the conjunctiva in 
reducing intraocular pressure (IOP) in eyes operated 
on for open-angle glaucoma combined with phaco-
emulsification and posterior chamber intraocular Jens 
(PC IOL) implantation. 
PATIENTS AND METHODS 
In this nonrandomized nonmasked prospective trial, the 
Ex-PRESS R-50 microtube was implanted in 35 eyes of 35 
patients at the Glaucoma Unit, Ophthalmology Depart-
ment, University of Lausanne, between November 2000 
and June 2002. The patients, nonconsecutive cases, were en-
rolled in this study after formai approval by the Ethical 
Committee of the University of Lausanne. Preference for 
this technique over other filtering surgery was based on 
the patient's willingness to participate in the study. Each 
patient received a comprehensive explanation of the study 
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and its implications and signed a written informed consent 
before surgery. 
Patients eligible for the study were aider than 18 years. Ali 
had medically uncontrolled primary open-angle glaucoma 
(POAG) or pseudoexfoliative glaucoma (PXFG) associated 
with cataract. Uncontrolled glaucoma was defined as ele-
vated IOP, a progression of optic nerve cupping, and/ or de-
terioration of the visual field as assessed by an experienced 
glaucoma specialist. Patients who had sicle effects from anti-
glaucoma medication and eyes that required good IOP con-
trai without medication were also included. Ali eyes were 
under maximum tolerated medical therapy (2 or more anti-
glaucoma medications), had previous fi!tering surgery that 
failed, or both. In eyes with a previous failed filtering sur-
gery, the quadrant used to implant the Ex-PRESS R-50 micro-
tube was different from that in the initial surgery. This 
approach was used to minimize interference with possible 
conjunctival scarring or remodeling reaction from the former 
surgery. The mean decrease in preoperative best corrected 
visual acuity (BCV A) was mainly due to cataract develop-
ment. The Jens opacities estimation was made by slitlamp 
examination, and this assessment was used for the indication 
of a combined procedure when glaucoma surgery was con-
comitantly required. Cataract extraction was proposed 
when the mean preoperative BCVA was worse than 0.7 or 
the patient reported disturbing glare in the presence of Jens 
opacities. 
Eyes with angle-closure glaucoma, normal-tension glau-
coma, neovascular glaucoma, or congenital or juvenile glau-
coma were excluded from the study. Filtering surgery 
performed Jess than 1 year before enrollment in this study 
and a monocular status were also criteria for exclusion. 
The primary outcome measure was the IOP. The second-
ary outcome measures were BCV A, use of antiglaucoma 
medications, and type and number of perioperative or post-
operative complications. Based on the cup-to-disc ratio, the 
severity of glaucoma was classified into 3 groups: early 
(0.30 to 0.59), moderate (0.60 to 0.79), and severe (0.80 to 
1.00). 
Daia Recorded Preoperatively 
On enrollment, ail patients had a comprehensive ophthal-
mic examination that included measurement of the distance 
BCV A using Snellen charts at 6 m, anterior segment slitlamp 
biomicroscopy, fundus evaluation, a single-reading IOP 
measurement with a Goldmann applanation tonometer 
(without diurnal fluctuation taken into account), and auto-
mated visual field evaluation (Octopus 101, Haag-Streit) 
within 6 months before enrollment. 
Glaucoma Drainage Implant 
The Ex-PRESS R-50 implant is a miniature glaucoma 
drainage device made of biocompatible stainless steel.9 The 
tube is 2.50 mm in overall length, with 2.00 mm being intra-
ocular. The external diameter is approximately 400 ~un 
(27 gauge) and the inner bore, 50 pm. A detailed description 
of the Ex-PRESS R-50 technique has been published.9 
Surgical Technique 
Ali operations were performed by the same experienced 
ophthalmic surgeon (AM.) using retrobulbar anesthesia 
consisting of 2 to 4 ml of a bupivacaine 0.75%, lidocaine 
hydrochloride 4%, and 50 ru hyaluronidase mixed solution. 
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A retrobulbar procedure was preferred to peribulbar to pre-
vent an increase in IOP during injection of the solution. 
Temporal sutureless clear corneal phacoemulsification cata-
ract extraction with in-the-bag acrylic hydrophilic foldable 
intraocular lens (IOL) implantation was performed first 
through a 3.5 mm incision; the ophthalmic viscosurgical 
device (OVD) was left in the anterior chamber. For implan-
tation of the Ex-PRESS R-50 device, a 2.0 to 4.0 mm circum-
ferential conjunctival opening was created 10.0 to 15.0 mm 
posterior to the !imbus. The device, mounted on its intro-
ducer, was slid under the conjunctiva and Tenon' s capsule 
into the anterior chamber and implanted radial to the !imbus 
and parallel to the iris through a preincision made with a 27-
gauge needle 2.0 mm from the !imbus. The introducer was 
then withdrawn and the conjunctiva closed with an 8-0 poly-
glactin (Vic1yl) running suture. No patch, such as Tutoplast 
or a graft, was used to cover the implant. The tüne required 
to implant the device was approximately 3 minutes. Postop-
erative treatment consisted of topical application of tobra-
mycin and dexamethasone 5 tünes a day followed by 
graduai tapering over approximately 4 weeks. 
Success Crileria 
Surgery was considered a complete success when the 
IOP was 18 mm Hg or Jess and 6 mm Hg or more without 
medication. The same criteria with or without medication 
were used to define qualified success. Surgery was consid-
ered a failure when IOP was higher than 18 mm Hg despite 
medication and/ or further glaucoma surgery was required 
or the implant explanted. Patients having removal of the im-
plant, and thus considered failed cases, were not included in 
the subsequent postoperative follow-ups. Postoperative bleb 
management and fibrosis modulation using the needling 
technique, with or without mitomycin-C (MMC) injection, 
were not a criterion for failure; in such cases, the patient 
data were classified as qualified success. 
Postoperative Follow-up 
The BCV A, IOP, number of medications, and complica-
tions were recorded preoperatively as well as 1 and 7 days 
and 1, 2, 3, 6, 9, 12, 24, 36, and 48 months after surgery. Fol-
low-up was more frequent when required by the clinical 
situation. 
Any complication was recorded and was defined as major 
or minor based on the clinical significance and importance 
over time. Evaluation of the complications was based on 
the surgeon's clinical experience. Cases of cornea-device 
contact and iris-device contact were assessed under slitlamp 
examination. Hyphema was considered present when blood 
collection was seen in the anterior chamber. Anterior cham-
ber depth was clinically assessed under slitlamp examina-
tion and was considered shallow when iridocorneal touch 
in the periphery was noticed. Choroidal detachment was ob-
served under indirect ophthalmoscopy. Complications were 
considered minor if they resolved spontaneously or required 
minimal surgical revision. The major complications required 
removal of the device and further filtering surgery. 
When the filtering bleb at any postoperative visit was en-
cysted or showed signs of fibrosis leading to an increase in 
IOP, subconjunctival injections of MMC were administered. 
The subconjunctival injections consisted of 0.05 to 0.1 mL of 
a MMC 0.02% solution injected beneath the filtering bleb un-
der topical anesthesia. Neodymium:YAG (Nd:YAG) capsu-
lotomy (Microruptor V, Meridian AG) was performed 
when visual acuity was reduced as a result of posterior cap-
sule opacification. Neodymium:YAG laser synechialysis was 
clone to liberate synechia when the tube was obstructed by 
iris strands. 
Statistical Analysis 
Data are expressed as the mean ± SD (minimum and 
maximum). Results were analyzed using a 1-way analysis 
of variance (ANOVA) and Student t test for parametric 
data (IOP), Wilcoxon signed-rank test for nonparametric 
data (BCV A, number of medications), and Kaplan-Meier 
survival curves at the end of follow-up using the log-rank 
test. Results were considered significant when P < .05. 
RESULTS 
The Ex-PRESS R-50 device was easily implanted with-
out perioperative complications in 35 eyes of 35 white 
patients with glaucoma and cataract. The mean age of 
the patients was 74.6 years ± 10.9 (SD) (range 49 to 90 
years). Table 1 shows the patients' data. 
The mean follow-up was 36.9 ± 18.2 months (range 
3.7 to 37.1 months). Twenty-eight, 26, 24, and 21 
patients completed the 1-, 2-, 3-, and 4-year follow-up, 
respectively. Three patients died, and 1 was lost to 
follow-up. 
Mean preoperative IOP (Table 1) decreased after 
surgery by 21 % (mean 15.3 ± 6.2 mm Hg; range 7 to 
Table 1. Patient data (N = 35). 
Parameter 
Eyes, n 
Male/ female, n (%) 
Mean age (y) ± SD 
White ethnicity, n (%) 
Diagnosis 
POAG 
PXFG 
Mean follow-up (mo) ± SD 
Lost to follow-up, n (%) 
Preoperative data 
IOP(mmHg) 
Mean± SD 
Range 
Snellen BCVA 
Mean± SD 
Range 
Mean medications (n) per patient± SD 
Previous glaucoma surgery, n (%) 
Severity of glaucoma (c/ d ratio) 
Early (0.3-0.59) 
Mod2rate (0.6-0.79) 
Severe (:2: 0.8) 
Result 
35 
12 (34.3)/23 (65.7) 
74.6 ± 10.9 
35 (100) 
22 (62.9) 
13 (37.1) 
36.9 ± 18.2 
4 (11.4) 
19.3 ± 6.3 
10-35 
0.47 ± 0.3 
0.01-1.00 
2.1±1.1 
3 (8.5) 
10 (28.6) 
9 (25.7) 
16 (45.7) 
BCVA = best corrected visual acuity; c/ d = cup to dise; IOP = intraoc-
u]ar pressure; POAG = primary open-angle glaucoma; PXFG = pseu-
doexfoliative glaucoma 
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38 mm Hg) at 6 months, 22% (15.1 ± 4.6 mm Hg; 10 
to 30 mm Hg) at 12 months, 29% (13.8 ± 2.8 mm Hg; 
9 to 18 mm Hg) at 24 months, 24% (14.6 ± 2.9 mm Hg; 
10 to 19 mm Hg) at 36 months, and 31 % (13.3 ± 2.0 
mm Hg; 10 to 17 mm Hg) at 48 months. The drop was 
significant between the preoperative and all postopera-
tive periods (P < .005, ANOV A and Student t test). The 
IOP curve dropped 1 week after surgery; the drop was 
followed by a slight rise that stabilized at approximately 
14 mm Hg without a significant variation in the IOP be-
tween 1 month and 48 months (Figure 1). 
The mean preoperative BCV A (Table 1) increased to 
0.74 ± 0.34 (range 0.05 to 1.00) at 48 months (P = 
.0003). The BCV A increase was slightly limited 
( < 1.0) due to systemic or retinal disease not related 
to the initial glaucoma diagnosis. The postoperative 
complications had no effect on the visual outcomes. 
Four patients had a BCV A worse than 0.6 as a result 
of vascular trouble (n = 2) or age-related macular 
degeneration (n = 2). 
The reduction in antiglaucoma medication after 
implantation of the Ex-PRESS R-50 device was 57% 
at 48 months, at which time 11 patients (35%) were 
receiving pharmacological treatment (P < .05); 4 pa-
tients were on 1 medication, 6 were on 2, and 1 was 
on 3. The number of antiglaucoma medications 
slightly increased over time (mean 0.4 at 6 months 
and 0.9 at 48 months) (Figure 2). This was probably 
due to a progressive loss of efficacy in the device' s fil-
tering fonction, despite good IOP control. 
Postoperative bleb management and fibrosis modu-
lation were performed in 10 eyes (28.6%). The treat-
ment included needling with or without MMC 
injections and Nd:YAG capsulotomy (Table 2). 
Table 3 shows the postoperative complications. The 
minor complications resolved spontaneously in less 
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Figure 2. Mean number of medications before surgery and at each 
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than a month in 7 of the 10 cases. In the eye that devel-
oped a shallow anterior chamber, the chamber re-
quired inflation with an injection of an OVD. An 
Nd:YAG laser iridoplasty was performed in an at-
tempt to solve the problem created by the iris-device 
contact. The contact did not resolve; thus, the eye re-
quired further surgical treatment. The cystic Tenon's 
capsule did not resolve despite revision of the filtering 
bleb consisting of a tenonectomy and synechialysis. 
Major complications occurred in 8 cases (Table 3). 
The cases of conjunctival erosion were induced by 
a protruding dislodged device. In the cases of com-
plete tube obstruction, there was significant and rapid 
elevation in IOP over early postoperative (1 to 8 week) 
values. Two obstructions occurred in patients with 
PXFG and 2 in patients with POAG. 
The device was removed in al! eyes with complica-
tions, all of which required further glaucoma filtering 
surgery. In 1 eye with conjunctival erosion, an attempt 
was made to implant a new Ex-PRESS R-50 device. 
This was followed by a new conjunctival erosion that 
required surgical removal of the new device. Three 
eyes that required tube removal had previous bleb 
management with MMC injection; the reasons for 
Table 2. Postoperative interventions. 
Intervention 
Needling with MMC 
Needling without MMC 
Nd:YAG capsulotomy 
MMC = mitomycin-C; Nd:YAG = neodymium:YAG 
Eyes 
Number (%) 
6 (17.1) 
4 (11.4) 
5 (14.3) 
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Table 3. Postoperative complications. 
Complication 
Min or 
Cornea-device contact at 1 day 
HyPhema <2.0 nun at 1 day 
Shallow anterior chamber requiring 
reformation 
Choroidal detachment in first postop week 
Iris-device contact at 8 months 
Fibrosis of Tenon's capsule at 10 months 
Major 
Erosion of the conjunctiva at 2, 6, 9, or 12 
months 
Obstruction of the tube at 6 months (n = 1) 
and 18 months (n = 3) 
Tube removal 
Number (%) 
1 (2.9) 
1 (2.9) 
1 (2.9) 
5 (14.3) 
1 (2.9) 
1 (2.9) 
4 (11.4) 
4 (11.4) 
10 (28.6) 
removing these tubes were tube occlusion in 2 eyes 
and conjunctival erosion in 1. 
At 48 months, based on the Kaplan-Meier survival 
curve, the cumulative qualified success rate was 
53.7% and the complete success rate was 32.7% 
(P < .05) (Figure 3). Based on IOP and surgical criteria, 
48.0% of patients had failed surgery. 
DISCUSSION 
Our study of 35 eyes found a 31 % reduction in IOP 48 
months postoperatively with a cumulative qualified 
success rate of 53.7%. Based on the percentage of IOP 
reduction, our results compare favorably with those 
in other studies.10- 15 Our results were obtained with 
a mean number of antiglaucoma medications that in-
creased slightly over time. However, considering the 
qualified success rate, our results were notas favorable 
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Figure 3. Qualified and cmnplete cumulative success rate (P < .05). 
as those reported in the literature for other filtering 
procedures; that is, 60% to 100% for trabeculec-
18-19 91 0/ 20 21 f . tomy, up to 10 ' or nonpenetratmg surgery, 
and 45% to 80% for other glaucoma drainage 
devices. 22- 25 
Two studies of the Ex-PRESS R-50 implant using the 
same surgical approach have been published. Traver-
so et al.10 implanted the device in 25 eyes and obtained 
a qualified success rate of 76.9%. Zarnowski et al.12 
treated 16 eyes with a qualified success rate of 68%. 
The authors report few complications, and both 
groups concluded that Ex-PRESS R-50 implantation 
is an effective and safe procedure. Their mean fol-
low-up (23.9 months and 6.0 months, respectively) 
was shorter than ours (36.9 ± 18.2 months), and this 
could explain the different results. 
Our results do not differ significantly from those of 
Wamsley et al.15 in terms of the degree of TOP reduc-
tion and the high rate of complications. Most compli-
cations we encountered were also observed by 
Stewart et al.16 in a small case series reporting compli-
cations after Ex-PRESS implantation and by Tavolato 
et al. 17 in a case report of a spontaneous extrusion of 
the Ex-PRESS device. The preoperative glaucoma his-
tory of these eyes, including the previous surgeries, as 
well as the type and severity of glaucoma were proba-
bly important risk factors for failure. For example, of 
the 10 cases that eventually ended as a failure, 2 had 
previous glaucoma surgery for medically uncon-
trolled glaucoma. 
In our study, the postoperative BCV A increased by 
approximately 60% 18 to 24 months after surgery. This 
improvement was the direct benefit of cataract 
extraction. No patient had a postoperative BCV A 
lower that the preoperative BCV A. 
The reduction in the mean number of medications 
was 57% at last follow-up. This result is encouraging; 
however, as the preoperative IOP was not significantly 
elevated, we essentially focused on lowering the num-
ber of medications rather than on IOP. The mean time 
before reintroducing medication was 10.5 ± 0.3 
months (range 1 to 36 months) after surgery. Lachkar 
et al. 21 report a mean time before restarting medica-
tions of 20.2 months after initial nonpenetrating deep 
sclerectomy and Chenet al., 18 of 41 months after initial 
trabeculectomy. Both techniques decreased the mean 
number of antiglaucoma medications (by 58% and 
48%, respectively) at the last postoperative follow-
up. In our cases, the reintroduction of antiglaucoma 
medication occurred sooner; on the other hand, the 
quantity of drugs increased over time. This could 
reflect a progressive loss of efficacy in the device' s fil-
tering fonction. Four of the 8 major complications in 
our study were due to tube obstruction that required 
additional treatment. 
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Studies of trabeculectomy report an increased rate 
of cataract development after surgery, 26 a complication 
not reported at the same rate for the long-term results 
of deep sclerectomy. 20 Therefore, it is interesting to 
contemplate a combined procedure that treats glau-
coma and cataract at the same time without compro-
mising either operation. For instance, some studies 
found better IOP reduction and a higher success rate 
when trabeculectomy was performed alone.27 Con-
trary to trabeculectomy, the effects of a nonpenetrating 
procedure did not appear to be compromised in terms 
of Iowering IOP when combined with phacoemulsifi-
cation and IOL implantation.28 When glaucoma drain-
age implants such as the Baerveldt tube or Molteno 
valve were used in conjunction with phacoemulsifica-
tion, the results also seemed favorable. 29 Comparing 
our results with those in studies that addressed the 
glaucoma issue only, no significant differences in 
1215 IOP-lowering effect or success rate was found. ' · 
While this conclusion could be compared with that 
reached for nonpenetrating surgery, follow-up and 
patient number were limited and further studies in-
volving more patients and a longer follow-up period 
are required. 
The surgical approach with the Ex-PRESS R-50 
implant differs significantly from previously reported 
filtering techniques. The 2 major complications, tube 
obstruction and conjunctival erosion, may be due 
to the small inner bore, which can become increas-
ingly clotted over time, and the plate touching the 
conjunctiva with significant rubbing of the edges of 
the plate. 
To alleviate complications that are mainly the result 
of conflict between tube design and eye anatomy, we 
propose improvements. For instance, the Iength and 
tube geometry could be redesigned to prevent the lu-
men from clotting. Similarly, to prevent conjunctival 
erosion, the distal end of the tube should be protected 
by covering it under a superficial scierai flap. This 
technique has been successfully tested. 9'13'14 
Our study had limitations. The number of patients 
enrolled (35) was relatively small, although this figure 
compares favorably with that in other published pa-
pers on this topic.rn-12'15 The design was nonmasked 
because the inner portion of the tube was visible to 
the investigators during slitlamp biomicroscopy ex-
amination. This could have led to an inevitable bias 
in the interpretation of the complications. Neverthe-
less, the investigators tried not to influence the quali-
fication of the complications based on their possible 
individual conceptions about this procedure. The non-
randomized and nonconsecutive selection of patients 
could also have contributed, to a Iesser extent, to 
some observer bias in proposing this technique based 
on individual presumptions. Again, care was taken to 
minimize such influence by performing the surgery 
based solely on the patient's clinical status and interest 
in being involved in the study. The strength of the 
study lies in the long follow-up and that the same 
technique was used by the same surgeon for al! 
surgeries. 
CONCLUSION 
In this paper, we present the Iong-term results of 
a study of combined glaucoma and cataract surgery 
comprising phacoemulsification and PC IOL implan-
tation followed by the implantation of the Ex-PRESS 
R-50 microtube. Of the 35 eyes analyzed, 10 (32%) 
had satisfactory IOP contrai without medication. A 
third of the tubes had to be explanted due to major 
complications that required further glaucoma surgery. 
Reasons for this surgical failure were tube obstruction 
and conjunctival erosion. Modifications of the tube' s 
geometry and the surgical technique may improve 
the efficiency and safety of the procedure. 
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